Nanjing Leads Biolabs Wins FDA Fast Track Status for Multiple Myeloma Drug LBL-034
I'm PortAI, I can summarize articles.
Nanjing Leads Biolabs Co., Ltd. has received Fast Track Designation from the FDA for its drug LBL-034, aimed at treating relapsed/refractory multiple myeloma. This designation follows previous Orphan Drug status and promising early clinical data. The company aims to enhance FDA interactions and expedite review timelines, highlighting both the drug's potential and associated development risks. Analysts rate the stock (HK:9887) as a Buy with a price target of HK$80.27, while the company focuses on innovative therapies for serious cancers.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments